Noemi Salang Ramsay, MD
Pain Medicine · Little Rock, ARNPI 1508822735
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 38.5% of the total. Reporting peaked in 2019 at $783 and has fallen 58.7% since, to $323 in 2025. That places this record below the midpoint for pain medicine clinicians in AR, where the typical reported total is $3,271.
Across 141 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$194
- Pacira Therapeutics, Inc.$186
- Scilex Pharmaceuticals Inc.$162
- Averitas Pharma Inc.$130
- MDD US Operations, LLC$128
- plus $934 from 24 others
What the payments were for
- Food & beverage$2,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 58 | $1,087 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $194 |
| Pacira Therapeutics, Inc. | 4 | $186 |
| Scilex Pharmaceuticals Inc. | 9 | $162 |
| Averitas Pharma Inc. | 2 | $130 |
| MDD US Operations, LLC | 1 | $128 |
| Daiichi Sankyo Inc. | 7 | $119 |
| Lilly USA, LLC | 6 | $88 |
| Boston Scientific | 2 | $72 |
| Amgen(2 entities) | 4 | $70 |
| AbbVie(2 entities) | 4 | $66 |
| Nevro Corp. | 3 | $56 |
| Pfizer | 4 | $55 |
| Zyla Life Sciences, Inc. | 4 | $53 |
| Biodelivery Sciences International, Inc. | 3 | $39 |
| Baudax Bio Inc. | 2 | $34 |
| Bioventus LLC | 2 | $33 |
| Stimwave Technologies Incorporated | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Redhill Biopharma Inc. | 2 | $27 |
| Medtronic | 1 | $20 |
| Vertex | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Kaleo, Inc. | 1 | $18 |
| Shionogi Inc | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Globus Medical | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| VGI Medical, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucemyra/Lofexidine$128
- Zilretta$120
- Qutenza$106
How this compares
$2,821 in reported general payments places this provider in the 40th percentile of 53 pain medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 38 | $93,759 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,280 | $42,000 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,202 | $37,043 |
| Xtampza ErOxycodone Myristate | 97 | $28,282 |
| Oxycodone Hcl | 1,093 | $21,062 |
| Gabapentin | 696 | $11,087 |
| Morphine Sulfate ErMorphine Sulfate | 475 | $10,163 |
| Pregabalin | 432 | $9,598 |
| Hysingla ErHydrocodone Bitartrate | 23 | $9,498 |
| MovantikNaloxegol Oxalate | 23 | $9,221 |
| Naloxone Hcl | 132 | $9,053 |
| Lidocaine | 58 | $7,905 |
| OxycontinOxycodone Hcl | 24 | $7,261 |
| Tizanidine Hcl | 494 | $4,557 |
| Buprenorphine | 11 | $4,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $194 | $93,75938 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $1,087 | $28,28297 claims |
| Redhill Biopharma Inc.Movantik | $27 | $9,22123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 53 pain medicine providers in Arkansas.
Other pain medicine in Little Rock
- Stephen PaulusLittle Rock$75K
- Julio OlayaLittle Rock$22K
- Christopher MocekLittle Rock$10K
- Ann IkonneLittle Rock$8K
- Saint AdeogbaLittle Rock$6K
- Andrew CainLittle Rock$5K
- Krishnappa PrasadLittle Rock$5K
- Thomas HartLittle Rock$4K
- James CaldwellLittle Rock$4K
- Terry FletcherLittle Rock$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.